Pasar al contenido principal

RETIRADA DEL TRATAMIENTO BETABLOQUEANTE EN PACIENTES CON INSUFICIENCIA CARDIACA CON FUNCION SISTOLICA PRESERVADA E INCOMPETENCIA CRONOTROPICA. EFECTO SOBRE LA CAPACIDAD FUNCIONAL

PI17/01426

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION HOSPITAL CLINICO UNIVERSITARIO DE VALENCIA
Centro realización INSTITUTO DE INVESTIGACION SANITARIA INCLIVA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Association between N-terminal pro-brain natriuretic peptide and maximal functional capacity in heart failure with preserved ejection fraction, The modifying role of obesity

  • Palau, Palau
  • Núñez, Gonzalo
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Miñana, Gema|||0000-0001-8777-2588
  • Domínguez, Eloy
  • Lorenzo, Miguel|||0000-0001-9182-4459
  • López, Laura
  • Flor, Cristina
  • Marín, Paloma
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sanchis, Juan|||0000-0003-0797-8709
  • Núñez, Julio|||0000-0003-1672-7119
This study investigates the association between maximal functional capacity (peakVO) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in 133 ambulatory patients with heart failure with preserved ejection fraction (HFpEF), focusing on patients with obesity. Across all participants, NT-proBNP inversely correlated with peakVO. However, this association varied based on obesity status. In patients without obesity, there was an inverse relationship between NT-proBNP and peakVO, while no significant correlation was observed in patients with obesity. These findings suggest that in stable ambulatory HFpEF, NT-proBNP did not predict peakVO in patients with obesity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction

  • Santas, Enrique
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Chorro, Francisco J
  • Palau, Patricia|||0000-0001-5040-0924
  • Miñana, Gema|||0000-0001-8777-2588
  • Heredia, Raquel
  • Amiguet, Martina
  • Merenciano, Héctor|||0000-0002-1734-0381
  • Sanchis, Juan|||0000-0003-0797-8709
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
Right ventricular dysfunction (RVD) parameters are increasingly important features in heart failure with preserved ejection fraction (HFpEF). We sought to evaluate the prognostic impact of a progressive RVD staging system by combining the tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (TAPSE/PASP) ratio with functional tricuspid regurgitation (TR) severity. We prospectively included 1355 consecutive HFpEF patients discharged for acute heart failure (HF). Of them, in 471 (34.7%) patients, PASP could not be accurately measured, leaving the final sample size to be 884 patients. Patients were categorized as Stage 1: TAPSE/PASP ≥ 0.36 without significant TR; stage 2: TAPSE/PASP ≥ 0.36 with significant TR; stage 3: TAPSE/PASP < 0.36 without significant TR; and stage 4: TAPSE/PASP < 0.36 with significant TR. By the 1 year follow-up, 207 (23.4%) patients had died. We found a significant and graded association between RVD stages and mortality rates (15.8%, 25%, 31.2%, and 45.4% from stage 1 to stage 4, respectively; log-rank test, p < 0.001). After multivariable adjustment, and compared to stage 1, stages 3 and 4 were independently associated with mortality risk (HR: 1.8219; 95% CI 1.308-2.538; p < 0.001 and HR = 2.2632; 95% CI 1.540-3.325; p < 0.001, respectively). A RVD staging system, integrating TAPSE/PASP and TR, provides a comprehensive and widely available tool for risk stratification in HFpEF.